



Changes to the Contract Drugs List (CDL)

Effective February 1, 2023

The below changes have been made to the [Contract Drugs List](#) posted to the Medi-Cal Rx Web Portal, effective February 1, 2023.

Drug Name	Description	Effective Date
Aminocaproic Acid	Added to CDL.	February 1, 2023
Baclofen	Additional formulation (oral suspension) added with restriction.	February 1, 2023
Busulfan	Updated Code I restriction.	February 1, 2023
Caffeine Citrate	Added to CDL with restriction.	February 1, 2023
Carmustine	Additional strengths (50 mg/vial, 300 mg/vial) added.	February 1, 2023
Chlorambucil	Updated Code I restriction.	February 1, 2023
Cyclophosphamide	Additional strength (200 mg/vial) added.	February 1, 2023
Mycophenolate Mofetil	Additional formulation (tablet) added.	February 1, 2023
Olutasidenib	Added to CDL with restriction.	February 1, 2023
Pexidartinib	Additional strength (125 mg) added with restriction.	February 1, 2023
Rivaroxaban	Additional formulation (suspension) added with restriction.	February 1, 2023
Sotalol HCL	Additional formulations (oral solution) added with restriction.	February 1, 2023
Thioguanine	Updated Code I restriction.	February 1, 2023

Drug Name	Description	Effective Date
Valganciclovir	Additional formulations (oral solution) added and Code I restriction removed.	February 1, 2023
Warfarin Sodium	Additional strength (6 mg) added.	February 1, 2023
DATA 2000 Waiver	Policy updated to remove requirement from medications used to treat opioid use disorder.	February 1, 2023

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@magellanhealth.com.